688192 Stock Overview Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Dizal (Jiangsu) Pharmaceutical Historical stock prices Current Share Price CN¥42.83 52 Week High CN¥51.15 52 Week Low CN¥24.82 Beta 0.23 1 Month Change -10.60% 3 Month Change 28.43% 1 Year Change -2.57% 3 Year Change 16.83% 5 Year Change n/a Change since IPO 4.21%
Recent News & Updates
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer Dec 11
Dizal Presents Latest Data of DZD8586, A Lyn/Btk Dual Inhibitor, in B-Cell Non-Hodgkin Lymphoma At the 2024 Ash Annual Meeting Dec 09
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Nov 08
Price target increased by 7.4% to CN¥56.00 Nov 05
Dizal Receives Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Oct 15
NMPA Approves Burning Rock and Dizal's First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China Oct 11 See more updates
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer Dec 11
Dizal Presents Latest Data of DZD8586, A Lyn/Btk Dual Inhibitor, in B-Cell Non-Hodgkin Lymphoma At the 2024 Ash Annual Meeting Dec 09
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Nov 08
Price target increased by 7.4% to CN¥56.00 Nov 05
Dizal Receives Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Oct 15
NMPA Approves Burning Rock and Dizal's First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China Oct 11
Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Sep 30
Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt? Aug 20
Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Jun 28
Dizal Announces the National Medical Products Administration of China Approves Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma Jun 19
New minor risk - Share price stability Jun 11
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Latest Data from the Inaugural Global Pivotal Study WU-KONG1 Part B (WU-KONG1B) of Sunvozertinib in Relapsed or Refractory Non-Small Cell Lung Cancer Jun 05
Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations May 25
Consensus revenue estimates decrease by 12% May 06
Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12% May 02
New major risk - Financial position May 02
Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024 May 01
Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt? Apr 30
New minor risk - Financial position Apr 30
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer Apr 24
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Apr 10
Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Mar 29
New major risk - Revenue and earnings growth Feb 25
Now 21% undervalued Jan 10
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine Dec 13
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH Dec 11
Consensus EPS estimates fall by 13% Nov 04
New major risk - Share price stability Oct 30
Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients Oct 24
Insufficient new directors Oct 01
Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL Sep 22
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL Sep 15
Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology Sep 12
New major risk - Revenue and earnings growth Sep 10
Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA Aug 18
Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Jun 28
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Compelling Data of Its Robust Oncology Portfolio At the 2023 American Society of Clinical Oncology Annual Meeting Jun 08
Price target increased by 11% to CN¥56.42 May 26
Dizal Announces Center for Drug Evaluation Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations Jan 11
Less than half of directors are independent Nov 16 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Sunvozertinib Meets Primary Endpoint in Its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO
Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 WCLC Aug 05
Dizal Pharmaceutical Announces Pre-Clinical and Clinical Results of Sunvozertinib (DZD9008) Published in Cancer Discovery May 06
First quarter 2022 earnings: EPS and revenues miss analyst expectations Apr 28
Less than half of directors are independent Apr 27
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 27
Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for Dzd4205 for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma Feb 19
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 (Sunvozertinib) for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Jan 28 Shareholder Returns 688192 CN Biotechs CN Market 7D -6.5% -1.9% -1.2% 1Y -2.6% -16.2% 11.8%
See full shareholder returns
Return vs Industry: 688192 exceeded the CN Biotechs industry which returned -16.2% over the past year.
Return vs Market: 688192 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility Is 688192's price volatile compared to industry and market? 688192 volatility 688192 Average Weekly Movement 8.7% Biotechs Industry Average Movement 8.8% Market Average Movement 8.7% 10% most volatile stocks in CN Market 12.8% 10% least volatile stocks in CN Market 5.7%
Stable Share Price: 688192 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688192's weekly volatility (9%) has been stable over the past year.
About the Company Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors. The company was founded in 2017 and is based in Shanghai, China.
Show more Dizal (Jiangsu) Pharmaceutical Co., Ltd. Fundamentals Summary How do Dizal (Jiangsu) Pharmaceutical's earnings and revenue compare to its market cap? 688192 fundamental statistics Market cap CN¥17.80b Earnings (TTM ) -CN¥837.22m Revenue (TTM ) CN¥389.64m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 688192 income statement (TTM ) Revenue CN¥389.64m Cost of Revenue CN¥13.65m Gross Profit CN¥375.99m Other Expenses CN¥1.21b Earnings -CN¥837.22m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.01 Gross Margin 96.50% Net Profit Margin -214.87% Debt/Equity Ratio 187.4%
How did 688192 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 20:23 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Dizal (Jiangsu) Pharmaceutical Co., Ltd. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Pei Cheng China Galaxy Securities Co., Ltd. Ziyu He China International Capital Corporation Limited Jin Zhang China International Capital Corporation Limited
Show 5 more analysts 
